Tillkännagivande • Jul 28
The Ensign Group, Inc. to Report Q2, 2026 Results on Jul 28, 2026 The Ensign Group, Inc. announced that they will report Q2, 2026 results on Jul 28, 2026 Reported Earnings • Jul 27
Second quarter 2026 earnings released: EPS: US$1.72 (vs US$1.48 in 2Q 2025) Second quarter 2026 results: EPS: US$1.72 (up from US$1.48 in 2Q 2025). Revenue: US$1.44b (up 17% from 2Q 2025). Net income: US$99.7m (up 18% from 2Q 2025). Profit margin: 6.9% (in line with 2Q 2025). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year. Tillkännagivande • Jul 27
The Ensign Group, Inc. Raises Earnings Guidance for the Year 2026 The Ensign Group, Inc. raised earnings guidance for the year 2026. Due to the strength of the second quarter, the company is increasing its annual 2026 earnings guidance to $7.75 to $7.85 per diluted share, up from the previously increased guidance of $7.48 to $7.62. The company is also increasing annual revenue guidance to $5.87 billion to $5.92 billion, up from $5.81 billion to $5.86 billion. The midpoint of the earnings guidance represents an 18.7% increase over 2025 and 41.8% over 2024. Declared Dividend • Jun 25
First quarter dividend of US$0.065 announced Shareholders will receive a dividend of US$0.065. Ex-date: 30th June 2026 Payment date: 31st July 2026 Dividend yield will be 0.2%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 4%. Cash payout ratio: 4%. Tillkännagivande • Jun 20
The Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before July 31, 2026 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0650 per share of Ensign common stock, payable on or before July 31, 2026, to shareholders of record as of June 30, 2026. Tillkännagivande • Jun 10
The Ensign Group, Inc. (NasdaqGS:ENSG) announces an Equity Buyback for $40 million worth of its shares. The Ensign Group, Inc. (NasdaqGS:ENSG) announces a share repurchase program. Under the program, the company will repurchase $40 million worth of common stock. Tillkännagivande • Apr 28
The Ensign Group, Inc. to Report Q1, 2026 Results on Apr 30, 2026 The Ensign Group, Inc. announced that they will report Q1, 2026 results on Apr 30, 2026 Tillkännagivande • Apr 04
The Ensign Group, Inc., Annual General Meeting, May 13, 2026 The Ensign Group, Inc., Annual General Meeting, May 13, 2026. Location: ensign services, inc, service center 29222 rancho, suite 127, san juan capistrano, california 92675., United States Tillkännagivande • Feb 05
The Ensign Group, Inc. Provides Earnings Guidance for the Year 2026 The Ensign Group, Inc. provided earnings guidance for the year 2026. For the period, the company expects annual 2026 earnings guidance of $7.41 to $7.61 per diluted share and annual revenue guidance of $5.77 billion to $5.84 billion. The midpoint of this 2026 earnings guidance represents an increase of 14.3% over 2025 results and is 36.5% higher than 2024 results. Tillkännagivande • Feb 03
The Ensign Group, Inc. to Report Q4, 2025 Results on Feb 04, 2026 The Ensign Group, Inc. announced that they will report Q4, 2025 results on Feb 04, 2026 Tillkännagivande • Dec 19
The Ensign Group, Inc. Increases Quarterly Cash Dividend, Payable on or Before January 31, 2026 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0650 per share of Ensign common stock, payable on or before January 31, 2026, to shareholders of record as of December 31, 2025. Tillkännagivande • Nov 04
The Ensign Group, Inc. Raises Earnings Guidance for the Year 2025 The Ensign Group, Inc. raised earnings guidance for the year 2025. For the year, the company expects earnings guidance to between $6.48 to $6.54 per diluted share, up from $6.34 to $6.46 per diluted share. The new midpoint of this increased 2025 earnings guidance represents an increase of 18.4% over 2024 results and is 36.5% higher than 2023 results. The company also increasing annual revenue guidance to $5.05 billion to $5.07 billion, up from $4.99 billion to $5.02 billion, to account for current quarter growth and acquisitions have closed and anticipate closing through the remainder of the year. Tillkännagivande • Oct 21
The Ensign Group, Inc. to Report Q3, 2025 Results on Nov 03, 2025 The Ensign Group, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025 Tillkännagivande • Sep 19
The Ensign Group, Inc. Declares A Quarterly Cash Dividend , Payable on or Before October 31, 2025 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common stock, payable on or before October 31, 2025, to shareholders of record as of September 30, 2025. Tillkännagivande • Sep 03
Ensign Pays over $47 Million to Settle Claims in Whistleblower Suit Alleging Fraud and Kickbacks Whistleblower Law Collaborative LLC, Hirst Law Group, P.C., and Bird, Marella, Rhow, Lincenberg, Drooks, & Nessim, LLP announced a settlement of over $47.3 million in a whistleblower case against The Ensign Group, Inc., and Ensign Services, Inc. ("Ensign"). The settled claims, brought in a lawsuit filed by a whistleblower in 2015, resolve allegations that Ensign knowingly engaged in fraud perpetrated against Medicare, Medicaid, and other government health care programs. The complaint, filed as a qui tam suit under the federal and California False Claims Acts (FCAs), alleged that nationwide Ensign knowingly paid kickbacks to physicians for referrals of patients to Ensign's skilled nursing facilities (SNFs) in violations of the FCAs, the federal and California Anti-Kickback Statutes, and the federal Stark self-referral law. The complaint also alleged that Ensign violated a previous Corporate Integrity Agreement (CIA) that Ensign signed with the Department of Health and Human Services (HHS) in 2013 as part of an earlier False Claims Act case settled by the company. The whistleblower worked as a former Contracts Manager at Ensign. In that role, she was responsible for reviewing, tracking, and monitoring contracts entered into by Ensign's Facilities. She also served on the Company's Compliance Committee where one of her responsibilities was to ensure that payment provisions in Ensign's contracts were in accordance with the law. The whistleblower alleged that she complained about the fraud she observed but could not get Ensign to change its conduct. As the second amended complaint alleged, as part of her work, the whistleblower observed, among other fraud, that: Ensign made inflated monthly payments to physicians to serve as medical directors and in other "consulting" capacities, when those excessive payments were designed to induce the doctors to refer patients to the Ensign's SNFs; Ensign SNF administrators admitted that while they used to pay for patient referrals with "donuts," they were now paying for referrals with "dollars"; Another Ensign administrator admitted that he performed a return on investment calculation to determine the number of referrals needed from each doctor to break even on the monthly payments made to those doctors -- and that he would raise or lower the payments to the doctors based on their number of referrals; and Ensign paid thousands of dollars each month for multiple medical directors and consultants. At one SNF alone, Ensign paid four doctors to serve as "medical directors" and paid at least ten additional doctors for "consulting agreements."The whistleblower alleged that she attempted to stop the fraud by changing the contracts to institute hourly rates tied to actual work and fair market value, rather than excessive monthly lump sum payments to induce referrals, but her attempts were overridden by Ensign. Whistleblower Law Collaborative and Hirst Law Group filed the FCAqui tam suit on behalf of the whistleblower, who alleged that Ensign had both engaged in fraud and failed to disclose its illegal conduct to the government as required. When the government allowed the whistleblower to proceed with the FCA suit in 2020, Whistleblower Law Collaborative and Hirst Law Group went forward with the case with Bird Marella as taint counsel. The team proceeded to successfully litigate the case for four years and were in the midst of discovery when the settlement was reached. Tillkännagivande • Jul 25
the Ensign Group, Inc. Raises Earnings Guidance for the Year 2025 The Ensign Group, Inc. raised earnings guidance for the year 2025. For the year, the company is raising annual 2025 earnings guidance to between $6.34 to $6.46 per diluted share, up from previously raised guidance of $6.22 to $6.38 per diluted share. The new midpoint of this increased 2025 earnings guidance represents an increase of more than 16% over 2024 results and is 34% higher than 2023 results. The company is also increasing annual revenue guidance to $4.99 billion to $5.02 billion, up from $4.89 billion to $4.94 billion, to account for current quarter performance and acquisitions company anticipate closing through the third quarter. Tillkännagivande • Jul 22
The Ensign Group, Inc. to Report Q2, 2025 Results on Jul 24, 2025 The Ensign Group, Inc. announced that they will report Q2, 2025 results on Jul 24, 2025 Tillkännagivande • Jun 21
The Ensign Group, Inc. Announces Board Changes, Effective September 1, 2025 The Ensign Group, Inc. announced that Christopher Christensen, Executive Chairman and member of the Ensign Board of Directors, has provided notice to the board of his intent to retire from both his roles effective September 1, 2025. Barry R. Port, Ensign’s Chief Executive Officer, has been appointed to serve as Chair of the Board of Directors, effective September 1, 2025. Mr. Port will continue to serve as Ensign’s Chief Executive Officer, a role he’s held since May 30, 2019. Prior to that, he served as Chief Operating Officer for Ensign Services, Inc. for five years and has been with the organization in various operational roles for over 21 years. Mr. Port has served as Chief Executive
Officer since May 2019 and is a currently a member of the board. Before becoming CEO, Mr. Port served as Chief Operating Officer at Ensign Services, Inc. from January 2012 to May 2019, overseeing field support and back-office services for affiliated skilled nursing and senior living operations nationwide. Prior to that, he was President of Keystone Care, Inc. from March 2006 to December 2011, where he provided operational oversight for facilities across Texas. Earlier in his career, he held various roles operating affiliated skilled nursing campuses in Arizona and Texas. In addition, Marivic Uychiat has been appointed to serve as a member of the Board of Directors, filling the vacancy on the board created by Mr. Christensen’s retirement, effective September 1, 2025. Ms. Uychiat has been a key contributor in the organization for over 22 years and has served as Executive Vice President of Clinical Services at Ensign Services, Inc. since 2016. Before assuming her current role, Ms. Uychiat served as Director of Clinical Services for the company’s California operations. Her extensive background also includes a decade-long tenure as Director of Nursing at Vista Knoll Specialized Care, where she oversaw comprehensive care for psychiatric/neuro-behavioral, dementia, and short-term post-acute rehabilitation patients. Ms. Uychiat holds a Bachelor's Degree in nursing, graduating Cum Laude from the University of St. La Salle. She also completed the Chief Nursing Officer program at University of California Irvine Paul Merage School of Business. She brings nearly three decades of leadership in the Skilled Nursing and Post-Acute Care industry to the board.Her professional expertise spans skilled healthcare management, clinical program development, and policymaking. Tillkännagivande • Jun 20
the Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before July 31, 2025 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common
stock, payable on or before July 31, 2025, to shareholders of record as of June 30, 2025. Tillkännagivande • Jun 03
The Ensign Group, Inc. (NasdaqGS:ENSG) acquired operations of Ironwood Rehabilitation and Care Center. The Ensign Group, Inc. (NasdaqGS:ENSG) acquired operations of Ironwood Rehabilitation and Care Center on June 1, 2025.
The Ensign Group, Inc. (NasdaqGS:ENSG) completed the acquisition of operations of Ironwood Rehabilitation and Care Center on June 1, 2025. Tillkännagivande • Apr 23
The Ensign Group, Inc. to Report Q1, 2025 Results on Apr 29, 2025 The Ensign Group, Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 29, 2025 Tillkännagivande • Apr 07
The Ensign Group, Inc., Annual General Meeting, May 15, 2025 The Ensign Group, Inc., Annual General Meeting, May 15, 2025. Location: 11701 studebaker road, calfornia 90650, norwalk United States Tillkännagivande • Mar 20
The Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before April 30, 2025 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common stock, payable on or before April 30, 2025, to shareholders of record as of March 31, 2025. Tillkännagivande • Feb 06
The Ensign Group, Inc. Provides Earnings Guidance for the Year 2025 The Ensign Group, Inc. provided earnings guidance for the year 2025. The company annual 2025 earnings guidance of $6.16 to $6.34 per diluted share and annual revenue guidance of $4.83 billion to $4.91 billion. The midpoint of this 2025 earnings guidance represents an increase of 13.8% over 2024 results and is 31.0% higher than 2023 results. Tillkännagivande • Feb 01
The Ensign Group, Inc. to Report Q4, 2024 Results on Feb 05, 2025 The Ensign Group, Inc. announced that they will report Q4, 2024 results on Feb 05, 2025 Tillkännagivande • Dec 13
The Ensign Group, Inc. Declares Quarterly Cash Dividend, Payable on or Before January 31, 2025 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0625 per share of Ensign common stock, payable on or before January 31, 2025, to shareholders of record as of December 31, 2024. Tillkännagivande • Nov 05
The Ensign Group, Inc. (NasdaqGS:ENSG) acquired Operations of Benedictine Living Community Wausau from Benedictine Living Communities, Inc. The Ensign Group, Inc. (NasdaqGS:ENSG) acquired Operations of Benedictine Living Community Wausau from Benedictine Living Communities, Inc. on November 1, 2024.
The Ensign Group, Inc. (NasdaqGS:ENSG) completed the acquisition of Operations of Benedictine Living Community Wausau from Benedictine Living Communities, Inc. on November 1, 2024. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: US$1.38 (vs US$1.14 in 3Q 2023) Third quarter 2024 results: EPS: US$1.38 (up from US$1.14 in 3Q 2023). Revenue: US$1.08b (up 15% from 3Q 2023). Net income: US$78.4m (up 23% from 3Q 2023). Profit margin: 7.3% (up from 6.8% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 25
The Ensign Group, Inc. Raises Earnings Guidance for the Full Year 2024 The Ensign Group, Inc. raised earnings guidance for the full year 2024. For the year, the company raising and narrowing annual 2024 earnings guidance to between $5.46 to $5.52 per diluted share, up from $5.38 to $5.50 per diluted share. The new midpoint of 2024 earnings guidance represents an increase of more than 15.1% of 2023 results and is 32.6% higher than 2022 results. The company also increasing annual revenue guidance to between $4.25 billion to $4.26 billion, up from previous guidance of $4.20 billion to $4.22 billion to account for current quarter growth and acquisitions anticipate closing by the end of the year. Tillkännagivande • Oct 22
The Ensign Group, Inc. to Report Q3, 2024 Results on Oct 24, 2024 The Ensign Group, Inc. announced that they will report Q3, 2024 results on Oct 24, 2024 Tillkännagivande • Oct 21
the Ensign Group, Inc. Appoints Mark Parkinson to the Board of Directors The Ensign Group, Inc. announced that the Board of Directors appointed Mark Parkinson to serve on the Board as its ninth director. In May of this year, Ensign shareholders, at the recommendation of the Board, voted to approve an amendment to the Company's Certificate of Incorporation, expanding the size of the Board from eight to nine members. Mr. Parkinson, who recently retired from his 14-year service as the President and CEO of the American Health Care Association (AHCA) and National Center for Assisted Living (NCAL), fills the vacancy created by the increase in size of the Board. Parkinsons appointment is for a term starting on October 21, 2024, and ending on the date of the Company's 2025 annual shareholders meeting. It is anticipated that the Board and the Nomination and Governance Committee of the Board will nominate Mr. Parkinson for election by shareholders at the 2025 Annual Shareholder meeting to serve as a Class II director for a two-year term ending at the Companys annual shareholder meeting in 2027. Parkinson has held several positions in both the public and private sector and is currently the Principal of the American Health Care Association and the National Center for Assisted Living (AHCA/NCAL), which represents more than 14,000 nursing homes, assisted living communities, and intermediate care facilities for individuals with disabilities. Previously, Parkinson was the associations President and CEO for 14 years from 2011 to 2024. Under Parkinsons leadership, AHCA/NCAL focused on delivering policy solutions to Congress and the Executive Branch, with a special emphasis on quality care. During his tenure, AHCA/NCAL remained the largest association in long term care and enjoyed record membership. Prior to his role as President and CEO for AHCA/NCAL, Parkinson served as the 45th Governor of the State of Kansas from 2009 to 2011, the 47th Lieutenant Governor of the State of Kansas from 2007 to 2009, and a Kansas state legislator. He also built, owned, and operated nursing home and senior living facilities in Kansas and Missouri between 1996 and 2006. Mr. Parkinson earned his Bachelor of Arts degree from Wichita State University and his Juris Doctor from the University of Kansas. Declared Dividend • Sep 23
Second quarter dividend of US$0.06 announced Shareholders will receive a dividend of US$0.06. Ex-date: 30th September 2024 Payment date: 31st October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 6%. Cash payout ratio: 20%. Tillkännagivande • Sep 13
the Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before October 31, 2024 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.06 per share of Ensign common stock, payable on or before October 31, 2024, to shareholders of record as of September 30, 2024. Tillkännagivande • Jul 27
The Ensign Group, Inc. Revises Earnings Guidance for the Year 2024 The Ensign Group, Inc. revised earnings guidance for the year 2024. The company raising and narrowing annual 2024 earnings guidance to between $5.38 to $5.50 per diluted share, up from $5.29 to $5.47 per diluted share. This new midpoint of 2024 earnings guidance represents an increase of more than 14% of 2023 results and is 31% higher than 2022 results. The company are also increasing annual revenue guidance to between $4.20 billion to $4.22 billion, up from previous guidance of $4.13 billion to $4.17 billion. Reported Earnings • Jul 26
Second quarter 2024 earnings released: EPS: US$1.26 (vs US$1.15 in 2Q 2023) Second quarter 2024 results: EPS: US$1.26 (up from US$1.15 in 2Q 2023). Revenue: US$1.04b (up 13% from 2Q 2023). Net income: US$71.0m (up 11% from 2Q 2023). Profit margin: 6.9% (in line with 2Q 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 24
The Ensign Group, Inc. to Report Q2, 2024 Results on Jul 25, 2024 The Ensign Group, Inc. announced that they will report Q2, 2024 results on Jul 25, 2024 Declared Dividend • Jun 24
First quarter dividend of US$0.06 announced Shareholders will receive a dividend of US$0.06. Ex-date: 28th June 2024 Payment date: 31st July 2024 Dividend yield will be 0.2%, which is lower than the industry average of 3.3%. Payout Ratios Payout ratio: 6%. Cash payout ratio: 7%. Tillkännagivande • Jun 15
The Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before July 31, 2024 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.06 per share of Ensign common stock, payable on or before July 31, 2024, to shareholders of record as of June 30, 2024. New Risk • May 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • May 02
First quarter 2024 earnings released: EPS: US$1.22 (vs US$1.08 in 1Q 2023) First quarter 2024 results: EPS: US$1.22 (up from US$1.08 in 1Q 2023). Revenue: US$1.01b (up 14% from 1Q 2023). Net income: US$68.8m (up 15% from 1Q 2023). Profit margin: 6.8% (up from 6.7% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Apr 28
The Ensign Group, Inc. to Report Q1, 2024 Results on May 01, 2024 The Ensign Group, Inc. announced that they will report Q1, 2024 results on May 01, 2024 Tillkännagivande • Apr 06
The Ensign Group, Inc., Annual General Meeting, May 16, 2024 The Ensign Group, Inc., Annual General Meeting, May 16, 2024, at 10:00 Pacific Daylight. Location: Southland Care Center 11701 Studebaker Road Norwalk, California 90650 california United States Agenda: To consider Election of two nominees named in the proxy statement to serve on The Ensign Group's Board of Directors; To consider Approval of the amendment to the Certificate of Incorporation to increase the size of The Ensign Group's Board of Directors to nine from eight. New Risk • Mar 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 02
Full year 2023 earnings released: EPS: US$3.76 (vs US$4.09 in FY 2022) Full year 2023 results: EPS: US$3.76 (down from US$4.09 in FY 2022). Revenue: US$3.73b (up 23% from FY 2022). Net income: US$209.4m (down 6.8% from FY 2022). Profit margin: 5.6% (down from 7.4% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 14% per year. Tillkännagivande • Feb 02
The Ensign Group, Inc. Provides Earnings Guidance for the Fiscal Year 2024 The Ensign Group, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects earnings guidance of $5.29 to $5.47 per diluted share and annual revenue guidance of $4.13 billion to $4.17 billion. Tillkännagivande • Jan 31
The Ensign Group, Inc. to Report Q4, 2023 Results on Feb 01, 2024 The Ensign Group, Inc. announced that they will report Q4, 2023 results on Feb 01, 2024 Buy Or Sell Opportunity • Jan 26
Now 20% undervalued Over the last 90 days, the stock has risen 17% to €105. The fair value is estimated to be €132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 13%. Buying Opportunity • Dec 16
Now 20% undervalued Over the last 90 days, the stock is up 16%. The fair value is estimated to be €127, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 23% in the next 2 years. Tillkännagivande • Dec 15
The Ensign Group, Inc. Increases Quarterly Dividend, Payable on or Before January 31, 2024 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.06 per share of Ensign common stock, payable on or before January 31, 2024, to shareholders of record as of December 31, 2023. Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: US$1.14 (vs US$1.02 in 3Q 2022) Third quarter 2023 results: EPS: US$1.14 (up from US$1.02 in 3Q 2022). Revenue: US$940.8m (up 22% from 3Q 2022). Net income: US$63.9m (up 14% from 3Q 2022). Profit margin: 6.8% (down from 7.3% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 26
The Ensign Group, Inc. Provides Earnings Guidance for 2023 The Ensign Group, Inc. provided earnings guidance for 2023. For the period, earnings guidance to between $4.73 to $4.79 per diluted share, up from $4.70 to $4.78 per diluted share. This new midpoint of 2023 earnings guidance represents an increase of 15.0% over 2022 results and is 30.8% higher than 2021 results. Company is raising annual revenue guidance to between $3.72 billion and $3.73 billion, up from previous guidance of $3.69 billion to $3.73 billion. Tillkännagivande • Oct 24
The Ensign Group, Inc. to Report Q3, 2023 Results on Oct 25, 2023 The Ensign Group, Inc. announced that they will report Q3, 2023 results on Oct 25, 2023 Tillkännagivande • Oct 07
The Ensign Group, Inc. (NasdaqGS:ENSG) acquired the Operations of Providence Place Ltcu The Ensign Group, Inc. (NasdaqGS:ENSG) acquired the Operations of Providence Place Ltcu on October 1, 2023.
The Ensign Group, Inc. (NasdaqGS:ENSG) completed the acquisition of the Operations of Providence Place Ltcu on October 1, 2023. Buying Opportunity • Sep 22
Now 20% undervalued Over the last 90 days, the stock is up 4.2%. The fair value is estimated to be €109, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 24% in 2 years. Earnings is forecast to grow by 25% in the next 2 years. Tillkännagivande • Sep 16
The Ensign Group, Inc. Declares Quarterly Dividend, Payable on October 31, 2023 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0575 per share of the company common stock, payable on or before October 31, 2023, to shareholders of record as of September 30, 2023. Tillkännagivande • Sep 06
The Ensign Group, Inc. (NasdaqGS:ENSG) acquired Two Skilled Nursing Facilities in South Carolina. The Ensign Group, Inc. (NasdaqGS:ENSG) acquired Two Skilled Nursing Facilities in South Carolina on September 1, 2023.The Ensign Group, Inc. (NasdaqGS:ENSG) completed the acquisition of Two Skilled Nursing Facilities in South Carolina on September 1, 2023. Tillkännagivande • Aug 03
The Ensign Group, Inc. (NasdaqGS:ENSG) and Standard Bearer Healthcare REIT, Inc. acquired Real estate and operations of Belmont Terrace and Puget Sound Transitional Care. The Ensign Group, Inc. (NasdaqGS:ENSG) and Standard Bearer Healthcare REIT, Inc. acquired Real estate and operations of Belmont Terrace and Puget Sound Transitional Care on August 1, 2023.The Ensign Group, Inc. (NasdaqGS:ENSG) and Standard Bearer Healthcare REIT, Inc. completed the acquisition of Real estate and operations of Belmont Terrace and Puget Sound Transitional Care on August 1, 2023. Tillkännagivande • Jul 29
The Ensign Group, Inc. Raises Earnings Guidance for the Year 2023 The Ensign Group, Inc. raised earnings guidance for the year 2023. The company are increasing and narrowing annual 2023 earnings guidance to between $4.70 to $4.78 per diluted share, up from $4.64 to $4.77 per diluted share. This new midpoint of 2023 earnings guidance represents an increase of 14.5% over 2022 results and is 30.2% higher than 2021 results. The company are also raising annual revenue guidance to between $3.69 billion to $3.73 billion, up from previous guidance of $3.68 billion to $3.73 billion. Reported Earnings • Jul 28
Second quarter 2023 earnings released: EPS: US$1.15 (vs US$1.05 in 2Q 2022) Second quarter 2023 results: EPS: US$1.15 (up from US$1.05 in 2Q 2022). Revenue: US$921.3m (up 26% from 2Q 2022). Net income: US$64.0m (up 11% from 2Q 2022). Profit margin: 6.9% (down from 7.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 26
The Ensign Group, Inc. to Report Q2, 2023 Results on Jul 27, 2023 The Ensign Group, Inc. announced that they will report Q2, 2023 results on Jul 27, 2023 Tillkännagivande • Jun 17
The Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before July 31, 2023 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.0575 per share of Ensign common stock, payable on or before July 31, 2023, to shareholders of record as of June 30, 2023. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: US$1.08 (vs US$0.92 in 1Q 2022) First quarter 2023 results: EPS: US$1.08 (up from US$0.92 in 1Q 2022). Revenue: US$886.8m (up 24% from 1Q 2022). Net income: US$59.9m (up 19% from 1Q 2022). Profit margin: 6.7% (down from 7.1% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 05
Full year 2022 earnings released: EPS: US$4.09 (vs US$3.57 in FY 2021) Full year 2022 results: EPS: US$4.09 (up from US$3.57 in FY 2021). Revenue: US$3.03b (up 15% from FY 2021). Net income: US$224.7m (up 15% from FY 2021). Profit margin: 7.4% (in line with FY 2021). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 21% per year. Tillkännagivande • Feb 01
The Ensign Group, Inc. to Report Fiscal Year 2022 Results on Feb 02, 2023 The Ensign Group, Inc. announced that they will report fiscal year 2022 results at 4:00 PM, US Eastern Standard Time on Feb 02, 2023 Tillkännagivande • Dec 24
The Ensign Group, Inc. Announces Board Changes In a letter received by the Board of Director of The Ensign Group, Inc. dated December 19, 2022, Lee A. Daniels announced his decision to resign from the Board effective on January 1, 2023 to focus on other endeavors. Mr. Daniels has served as member of the Board since June 2013. At the time of his resignation, he was serving as the Chair of the Compensation Committee. Mr. Daniels will continue his service on the Board and his respective committee assignments until his resignation is effective on January 1, 2023. During a meeting on the same day, the Board appointed John O. Agwunobi, M.D., to fill the vacancy created by Mr. Daniel’s resignation. Dr. Agwunobi’s appointment is for a term starting on January 1, 2023 and ending on the date of the Company’s 2023 annual shareholders meeting. It is anticipated that the Board will nominate Dr. Agwunobi for election by shareholders at the Company's 2023 annual shareholders meeting to serve as a Class III director for a two-year term ending at the Company’s annual shareholder meeting in 2025. Dr. Agwunobi has held several positions in both the public and private sector. From March 2020 until October 2022, Dr. Agwunobi served as Chief Executive Officer and Chairman of Herbalife Nutrition Inc. Previously, Dr. Agwunobi served as Chief Health and Nutrition Officer at Herbalife, responsible for training, education, science strategy and product development since 2016. He has also served as Co-President of Herbalife from May 2018 to April 2022. Prior to joining Herbalife, Dr. Agwunobi was an independent consultant, advising a number of privately-held health-related companies, including serving as an advisory board member of Shopko Stores Operating Co., LLC on behalf of the private equity firm Sun Capital Partners. He also served as a member of the board for Magellan Health Inc., a for-profit managed health care company focused on special populations, complete pharmacy benefits and other specialty areas of healthcare from December 2014 to June 2019. From September 2007 to April 2014, Dr. Agwunobi served as Senior Vice President and President of Health and Wellness for Walmart Inc. in the United States, where he grew the business and provided insight and advice on the company’s health reform position. From December 2005 to September 2007, he served as the Assistant Secretary of Health for the U.S. Department of Health and Human Services, where he was responsible for disease prevention and health promotion. His responsibilities included the oversight of the Centers for Disease Control, National Institute of Health, the U.S. Food and Drug Administration, the Office of the U.S. Surgeon General, and numerous other public health offices and programs. Dr. Agwunobi currently serves as a director for Blue Bird Bio Inc., a post that he has held since June 2017. He is also currently serving as a member of the board of the U.S. African Development Foundation and has been serving in that capacity since 2008. Also, effective January 1, 2023, the Board also appointed Ms. Abbott to serve as the Chair of the Compensation Committee with Mr. Barry M. Smith and Mr. Shaw. No changes were made to the Nomination and Corporate Governance Committee. Tillkännagivande • Dec 03
The Ensign Group, Inc. (NasdaqGS:ENSG) acquired Two Skilled Nursing Facilities in Colorado. The Ensign Group, Inc. (NasdaqGS:ENSG) acquired Two Skilled Nursing Facilities in Colorado on December 1, 2022.The Ensign Group, Inc. (NasdaqGS:ENSG) completed the acquisition of Two Skilled Nursing Facilities in Colorado on December 1, 2022. Tillkännagivande • Nov 09
The Ensign Group, Inc. (NasdaqGS : ENSG) entered into an agreement to acquire Twenty skilled nursing operations in the state of California from Sabra Health Care REIT, Inc. (NasdaqGS : SBRA). The Ensign Group, Inc. (NasdaqGS : ENSG) entered into an agreement to acquire Twenty skilled nursing operations in the state of California from Sabra Health Care REIT, Inc. (NasdaqGS : SBRA) on November 7, 2022. The transaction is subject to completion of certain regulatory approvals. The transaction is expected to be completed by February 1, 2023. Tillkännagivande • Nov 03
The Ensign Group, Inc. (NasdaqGS : ENSG) acquired Operations of Lila Doyle Post Acute. The Ensign Group, Inc. (NasdaqGS : ENSG) acquired Operations of Lila Doyle Post Acute on November 1, 2022.The Ensign Group, Inc. (NasdaqGS : ENSG) completed the acquisition of Operations of Lila Doyle Post Acute on November 1, 2022. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: US$1.02 (vs US$0.87 in 3Q 2021) Third quarter 2022 results: EPS: US$1.02 (up from US$0.87 in 3Q 2021). Revenue: US$770.0m (up 15% from 3Q 2021). Net income: US$56.2m (up 19% from 3Q 2021). Profit margin: 7.3% (up from 7.1% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 33% per year. Tillkännagivande • Oct 27
The Ensign Group, Inc. Increases Annual Earnings Guidance for 2022 The Ensign Group, Inc. announced that the company is raising annual 2022 earnings guidance again to $4.10 to $4.18 per diluted share, up from the previously increased guidance of $4.05 to $4.15 per diluted share. In addition, the company is raising annual revenue guidance to $3.01 billion to $3.03 billion, up from the previously increased revenue guidance of $2.96 billion to $3.0 billion. The new midpoint of this new 2022 earnings guidance represents an increase of 14% over 2021 results and is 32% higher than 2020 results. Tillkännagivande • Oct 25
The Ensign Group, Inc. to Report Q3, 2022 Results on Oct 26, 2022 The Ensign Group, Inc. announced that they will report Q3, 2022 results on Oct 26, 2022 Tillkännagivande • Sep 17
The Ensign Group, Inc. Declares Quarterly Cash Dividend, Payable on or before October 31, 2022 On September 16, 2022, The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.055 per share of the company's common stock, payable on or before October 31, 2022, to shareholders of record as of September 30, 2022. Reported Earnings • Aug 02
Second quarter 2022 earnings released: EPS: US$1.05 (vs US$0.91 in 2Q 2021) Second quarter 2022 results: EPS: US$1.05 (up from US$0.91 in 2Q 2021). Revenue: US$732.5m (up 15% from 2Q 2021). Net income: US$57.7m (up 17% from 2Q 2021). Profit margin: 7.9% (up from 7.7% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 3.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 30
The Ensign Group, Inc. to Report Q2, 2022 Results on Aug 01, 2022 The Ensign Group, Inc. announced that they will report Q2, 2022 results on Aug 01, 2022 Tillkännagivande • Jun 18
The Ensign Group, Inc. Declares Quarterly Dividend, Payable on or Before July 31, 2022 The Ensign Group, Inc. announced that it has declared a quarterly cash dividend of $0.055 per share of Ensign common stock, payable on or before July 31, 2022, to shareholders of record as of June 30, 2022. 
